Bioequivalence and Bioavailability Forum 14:49 CEST

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

Sundar.M
Junior

India,
2018-09-27 11:11

Posting: # 19330
Views: 248
 

 RSABE - Sequence [RSABE / ABEL]

Dear all,

What would be the advantages/disadvantages of following 6 sequences (TRR, RTR, RRT, RTT, TRT and TTR) in a RSABE design, instead of 3 sequences as per FDA recommendations. Your comments are highly appreciated.


Thanks
Sundar. M
Helmut
Hero
avatar
Homepage
Vienna, Austria,
2018-09-28 13:15

@ Sundar.M
Posting: # 19337
Views: 195
 

 Suggested: TRT|RTR

Hi Sundar,

» […] advantages/disadvantages of following 6 sequences (TRR, RTR, RRT, RTT, TRT and TTR) in a RSABE design, instead of 3 sequences as per FDA recommendations.

Advantages
  • Additionally to the estimate of CVwR you get the one of CVwT (good to know esp. if your study is a pilot and you want to design a pivotal study where CVwR ≠ CVwT). In the partial replicate you have to assume that CVwR = CVwT.
  • If swR <0.294 (only ABE acceptable) no convergence issues in the mixed-effects model with the FDA’s covariance-specification.
Disadvantages
  • Sample size is a multiple of six (instead of three in the partial replicate and two in the three-period full replicate).
  • Design currently not implemented in PowerTOST’s function sampleN.RSABE().
If you want to kill two birds with one stone I recommend the three-period two-sequence full replicate design (TRT | RTR) instead.

Cheers,
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. ☼
Science Quotes
Sundar.M
Junior

India,
2018-09-28 13:36

@ Helmut
Posting: # 19338
Views: 191
 

 Suggested: TRT|RTR

Thank you HS!
Back to the forum Activity
 Thread view
Bioequivalence and Bioavailability Forum |  Admin contact
18,761 posts in 3,996 threads, 1,258 registered users;
online 13 (0 registered, 13 guests [including 10 identified bots]).

A drug is that substance which, when injected into a rat,
will produce a scientific report.    Anonymous

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed